Evans Syndrome
7
3
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
Severe Immune Cytopenia Registry Www.Sic-reg.Org
OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
Tacrolimus Treatment for Refractory Autoimmune Cytopenia
Sirolimus for Autoimmune Disease of Blood Cells
Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome